Amylyx reports Q3 product revenue $102.7M, net income $20.9M, PHOENIX topline Q2 2024

Amylyx Pharmaceuticals, Inc.

2023-Q3 EPS reported $0.63 revenue$272,337,000

Net product revenue $102.7M (Q3) vs $98.2M (Q2 2023) and $0.3M (Q3 2022).
Net income $20.9M ($0.30 diluted EPS) compared to net loss $53.8M in Q3 2022.
Cash, equivalents and short-term investments $355.0M at Sept 30, 2023.
Post hoc analysis: median overall survival 10.4 months longer with AMX0035 vs historical control.
CHMP reaffirmed negative EU opinion; final decision end 2023. PHOENIX Phase 3 topline expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amylyx Pharmaceuticals, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $102.7 million, net income $20.9 million, EPS $0.30 on a fully diluted per share basis.

Period: the fiscal quarter ended September 30, 2023
Revenue: $102.7 million
Net income: $20.9 million
EPS: $0.30 on a fully diluted per share basis
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results ˗ Third quarter 2023 product revenue of $102.7 million; bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch ˗ Strong financial position supported by $20.9 million of net income during the

View on SEC.gov

Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.